StockData
Fennec Pharmaceuticals Inc. logo

Fennec Pharmaceuticals Inc. (FENC) company profile

FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3088% above fair value
$13.58+0.82 (+6.43%)

Close on Nov 17, 2026Market cap $476.21MP/E –Yield –

About Fennec Pharmaceuticals

Biological Products, (No Diagnostic Substances), SIC 2836

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on preventing cisplatin-induced hearing damage in cancer patients. Its primary commercial product is sodium thiosulfate injection, marketed as PEDMARK in the United States and PEDMARQSI in Europe, the United Kingdom, Australia, and New Zealand. The therapy reduces the risk of ototoxicity in pediatric patients aged one month and older who have localized, non-metastatic solid tumors and are receiving cisplatin chemotherapy. The company's end users are pediatric oncology patients, while its direct customers and distribution partners include hospitals, academic medical centers, community oncology clinics, specialty pharmacies, and international commercial partners.

The company is incorporated under the laws of British Columbia and maintains active subsidiaries in Delaware and Ireland. In the United States, its treatment is supplied to specialized pediatric hospitals and community oncology practices. Internationally, the company commercializes its product through third-party partners across Europe, Australia, New Zealand, Turkey, and Gulf Cooperation Council countries, with commercial availability established in Germany and the United Kingdom.

Summary of the business section of Fennec Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Fennec Pharmaceuticals Inc.
Headquarters
Research Triangle Park, NC
Address
Po Box 13628, 68 Tw Alexander Drive 27709
Phone
(919) 636-4530
Employees
35, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
A1
Fiscal year ends
December 31
Auditor
HASKELL & WHITE LLP, Irvine, California

Stock & identifiers

Ticker
FENC
Former tickers
FENCF until Nov 13, 2025; ADHXF until May 15, 2015
Exchange
Nasdaq
IPO date
Sep 15, 2017
Shares outstanding
35M, Aug 11, 2026
Public float
$106.05M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-3 reverse, Nov 13, 2014; 1-for-18 reverse, Aug 25, 2011
SEC CIK
1211583
CUSIP
31447P100
ISIN
CA31447P1009
FIGI
BBG000DTH814
Share class FIGI
BBG001S69M23
LEI
5299003IE70ITO2CBM73
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jeffrey S. HackmanChief Executive Officer, Director70,844
Christiana Marie CioffiChief Strategy Officer28,902
Pierre Sargis SayadChief Medical Officer13,701
Terry L. EvansChief Commercial Officer24,181
Robert AndradeCHIEF FINANCIAL OFFICER248,558
Marco Maria BrugheraDirector0
Jodi A. CookDirector–
Khalid IslamDirector133,333
Chris A. RallisDirector63,077

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.72M$815.46K$4.12M$103–
FY2024
Mr.Hackman
$1.61M$1.87M$1.12M$85–
FY2024
Mr.Raykov
$3.24M$1.96M$1.12M$85–
FY2023$2.50M$4.53M$1.23M$151–
FY2022$614.16K$1.57M$428.92K$129–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsTotalvs. prior year
Jeffrey Hackman
CEO
$586.34K$45.83K$887.10K$202.88K$1.72M+7%
Robert Andrade
CFO
$482.10K$70.55K$1.12M$202.88K$1.87M+6%
Pierre S. Sayad
CMO
$464.08K–$311.00K–$775.08K+60%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 35 employees, 19 of whom are in our commercial organization, and the rest of whom are in our G&A organization.”

Corporate history

Events identified from SEC filings

DateEventDetails
Sep 11, 2017ListingRegistration of securities on an exchange (Form 8-A)
May 17, 2017Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 14, 2014Name changeName changed from ADHEREX TECHNOLOGIES INC to Fennec Pharmaceuticals Inc.
Nov 15, 2013Late filingNotification of late filing
Aug 16, 2010Late filingNotification of late filing
Jul 17, 2009DeregistrationTermination of SEC registration (Form 15)
Jan 20, 2009DelistingNotice of delisting from exchange (Form 25)
Jan 13, 2009Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 11, 2008Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)

See a number that looks wrong?